Objective To evaluate the effect of inducing differenation of all trans retinoic acid (ATRA) on immunologic function of patients with gastric cancer. Methods T-lymphocyte subsets(T-Ls) and interleukin-2 receptor(sIL-2R) of 56 patients with gastric cancer after treatment of ATRA were studied. Results In radical gastric cancer resection group, the serum CD3,CD4 and CD4/CD8 rate were higher and sIL-2R were lower than those in the control group, after treatment of ATRA, CD3,CD4 and CD4/CD8 rate and sIL2R were as high as those in the control group. In the non-operative or palliative gastric resection group, CD3,CD4 and CD4/CD8 rates were increased markedly and the serum sIL-2R was decreased significantly than those in the control group. Conclusion ATRA inducing differenation can improve the immunity of the patients with gastric cancer.
Objective To observe the efficacy of all trans retinoic acid (ATRA) combined with 5-Fu on treating subcutaneously implanted gastric carcinoma SGC 7901 in the nude mice. Methods Thirty-two nude mice bearing tumor were randomly divided into 4 groups: control group (group A), ATRA 1 000 μg/d orally taken group (group B), 5-Fu 27 mg/kg group peritoneally injected (group C), 5-Fu 13.5 mg/kg combined with ATRA 500 μg/d group (group D). Results Significant inhibition of tumor growth was shown in the group B, group C and group D as compared with group A (Ｐ＜0.01), with the tumor growth inhibition rate and the tumor weight inhibition rate at the 7 weeks after the treatment being 56.88%, 49.00%, 70.00% and 56.10%, 51.64%, 76.95%. Conclusion ATRA combined with 5-Fu can enhance the effects of 5-Fu in treating gastric carcinoma.
ObjectiveTo investigate the existence of persistent systemic inflammation (PSI) among patients with chronic obstructive pulmonary disease (COPD) in local areas, and identify the risk factors of PSI.MethodsA total of 150 patients with stable COPD and 70 non-smoking healthy individuals were enrolled in our study. The levels of interleukin-6 (IL-6), IL-18 and activin A in serum were detected. Pulmonary function was tested, and basic information of the candidates was acquired at the same time. All of the patients were followed-up at 6 months, 12 months and 24 months for two years. The value at the 95th percentile of the concentration of inflammation markers of non-smoking healthy samples was defined as the threshold value, also known as normal ceiling limit value. Existence of PSI was defined as the condition that two or more kinds of inflammation markers exceed the threshold at each follow-up visit. The COPD patients were categorized into three classes, in which there were respectively none, one and two or more kinds of inflammation markers with over-threshold values. Based on a 2-year followup, patients with two or more kinds of inflammation markers exceeding threshold values were classified as PSI subgroup, and patients without inflammation markers exceeding threshold values as never inflamed subgroup.ResultsThere were 22 patients (14.7%) had persistent systemic inflammation, whereas 60 patients (40.0%) did not show evidence of systemic inflammation. Single factor analysis of two subgroups showed that the patients in PSI subgroup had higher body mass index (BMI), higher smoking index, higher prior frequency of time to exacerbation, higher proportion of patients at high risk for recurrent acute exacerbation during 2-year followup, higher SGRQ total score, lower FEV1%pred and lower FEV1/FVC ratio significantly (all P<0.05). Higher BMI and higher risk of recurrent acute exacerbation were independent risk factors leading to PSI, of which the higher risk of recurrent acute exacerbation had a more important effect on PSI.ConclusionsSome COPD patients have PSI in this region, which may constitute a novel COPD phenotype (called systemic inflammatory phenotype). Higher BMI and higher risk of recurrent acute exacerbation are independent risk factors leading to PSI. Individualized treatment to prevent acute exacerbation and appropriate weight control may be a better intervention for these patients.